Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERMES: Ziltivekimab in HF with mildly reduced or preserved EF and systemic inflammation
jRCT2031230085Recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in heart failure with mid-range ejection fraction (HFmrEF), heart failure with preserved ejection fraction (HFpEF) and chronic inflammation comparing Ziltivekimab arm with Placebo arm (2 arms). Primary endpoint: Time to first occurrence of composite HF endpoint. Started May 2023; status: recruiting.
02
Drugs
ziltivekimab
03
Conditions
heart failure with mid-range ejection fraction (HFmrEF)heart failure with preserved ejection fraction (HFpEF)chronic inflammation
Beyond the preview
Go deeper on jRCT2031230085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230085.